# US 2021/0330748 A1 · Semaglutide for use in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330748 A1
- Document ID: US20210330748A1
- Status: Published application
- Kind: A1
- Application number: 15/931,093
- Filed: 2020-05-13
- Published: 2021-10-28
- Earliest claimed: 2020-04-27
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Martin Linder; Mads Sundby Palle; Lars Holm Damgaard
- Web page: https://patentgrep.com/patent/US20210330748A1

## CPC

- A61K 38/26: Glucagons
- A61K 47/02: Inorganic compounds
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.

## Claims

### Claim 1

A method of treating non-alcoholic steatohepatitis (NASH), comprising administrating semaglutide in an amount in the range of about 0.7 to about 5 mg per week to a subject diagnosed with NASH.

### Claim 2 (depends on 1)

The method according claim 1, wherein the subject has liver fibrosis stage 1, liver fibrosis stage 2 or liver fibrosis stage 3, wherein the liver fibrosis stage is classified according to the Kleiner fibrosis classification.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the method further comprises chronic management of NASH.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the semaglutide is the sole active ingredient administered to the subject.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the semaglutide is administered by subcutaneous administration.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method according to claim 1, wherein the semaglutide is administered in an amount in the range of about 2.0 to about 3.5 mg per week.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the semaglutide is administered in an amount of about 2.4 mg per week.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the semaglutide is administered in an amount of 2.4 mg per week.

### Claim at position 11

-12. (canceled)

### Claim 13 (depends on 10)

The method according to claim 10, wherein the semaglutide is administered once daily or less frequent.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the semaglutide is administered once weekly.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the method provides no worsening of liver fibrosis in the subject.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the semaglutide is administered in a pharmaceutical composition in the form of an aqueous solution comprising one or more pharmaceutically acceptable excipients.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the pharmaceutical composition is an aqueous solution comprising about 1.0 mg/ml semaglutide, about 1.42 mg/ml disodium hydrogen phosphate dihydrate, about 14.0 mg/ml propylene glycol, about 5.50 mg/ml phenol, and is at a pH of about 7.4.

### Claim 18

A method of treating non-alcoholic steatohepatitis (NASH), comprising administrating an effective amount of semaglutide to a subject diagnosed with NASH, wherein the subject has liver fibrosis stage 2 or liver fibrosis stage 3, wherein the liver fibrosis stage is classified according to the Kleiner fibrosis classification, and wherein the semaglutide is administered in an amount in the range of about 0.7 to about 5 mg per week.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the semaglutide is administered in an amount in the range of about 2.0 to about 3.5 mg per week.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the semaglutide is administered in an amount of about 2.4 mg per week.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the semaglutide is administered in an amount of 2.4 mg per week.

### Claim at position 21

-23. (canceled)

### Claim 24 (depends on 20)

The method according to claim 20, wherein the semaglutide is administered once weekly.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the semaglutide is administered once weekly.

### Claim at position 24

-27. (canceled)

### Claim 28 (depends on 25)

The method according to claim 25, wherein the semaglutide is the sole active ingredient administered to the subject.

### Claim 29 (depends on 25)

The method according to claim 25, wherein the semaglutide is administered by subcutaneous administration.

### Claim 30 (depends on 25)

The method according to claim 25, wherein the semaglutide is administered in a pharmaceutical composition in the form of an aqueous solution comprising one or more pharmaceutically acceptable excipients.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the pharmaceutical composition is an aqueous solution comprising about 1.0 mg/ml semaglutide, about 1.42 mg/ml disodium hydrogen phosphate dihydrate, about 14.0 mg/ml propylene glycol, about 5.50 mg/ml phenol, and is at a pH of about 7.4.
